AcquisitionsJul 16, 2026, 05:17 PM
Jasper Acquires Kira Pharma, Secures $132M Investment
AI Summary
Jasper Therapeutics, Inc. announced the completion of its all-stock acquisition of Kira Pharmaceuticals, a company focused on complement therapies. Concurrently, Jasper secured a $132 million private placement from leading life sciences investors. Additionally, Kira out-licensed two assets, KP-301 and KP-402, to Mirador Therapeutics for an upfront payment of $12 million plus potential milestones. These transactions are expected to fund the combined company's operations and multiple clinical milestones through the second half of 2028, including advancing KP-104, briquilimab, and KP-701.
Key Highlights
- Jasper completed the all-stock acquisition of Kira Pharmaceuticals.
- Secured a concurrent $132 million private placement for non-voting convertible preferred stock.
- Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront.
- Combined financing and transactions expected to fund operations through H2 2028.
- Pipeline includes KP-104 (Phase 2/3 ready), briquilimab (late-stage), and KP-701 (preclinical).
- Jasper's pre-acquisition equityholders will own 6.68% of the combined company.
- Kira's pre-acquisition equityholders will own 49.86% of the combined company.
- Private placement investors will own 43.46% of the combined company.
Price Impact
More from JSPR